Teva Swings to Q2 Loss on $724M Emalex Charge; Terminates ADS Program
TEVA has more than doubled off its 52-week low of $14.99 on elevated volume (2.8× avg).
Summary
Teva's Q2 2026 results swung to a loss on a large acquisition-related charge, while the company also announced the termination of its ADS program and a direct NYSE listing of ordinary shares.
Key Events · Earnings and Guidance · TEVA
-
Q2 Net Loss of $576M
Net loss attributable to Teva was $576 million, compared to net income of $282 million in Q2 2025, primarily due to a $724 million acquired IPR&D charge for the Emalex acquisition.
-
Operating Loss Driven by R&D Surge
Operating loss was $231 million vs. income of $455 million a year ago. R&D expenses jumped to $970 million from $244 million, mainly from the Emalex deal.
-
Legal Costs Rise
Legal settlements and loss contingencies increased to $230 million from $166 million, driven by antitrust litigation provisions and opioid settlement updates.
-
ADS Program Termination Announced
Teva will terminate its ADS program and directly list ordinary shares on the NYSE, effective September 14, 2026. ADS holders will receive ordinary shares on a 1-for-1 basis.
Analysis · TEVA · Life Sciences
Teva reported a sharp swing to a net loss of $576 million in Q2 2026, driven by a $724 million acquired IPR&D charge for the Emalex acquisition. Operating income flipped to a $231 million loss, and R&D expenses nearly quadrupled. Legal costs also rose. Separately, the company announced it will terminate its ADS program and directly list ordinary shares on the NYSE, a structural change for U.S. investors. The CEO and other officers adopted 10b5-1 trading plans, which may signal planned insider sales.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 36.1% of the 1753 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TEVA was trading at $34.73 on NYSE in the Life Sciences sector, with a market capitalization of approximately $36.5B. The 52-week trading range was $14.99 to $37.35. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.